1376191-26-2

Upstream product

• 870812-32-1 (R)-N¹,N¹-dimethyl-4-(phenylthio)butane-1,3-diamine 
• 6668-56-0 4-fluoro-3-nitrobenzene-1-sulfonyl chloride 
• 14235-81-5 4-Ethynylaniline 
• 1493-27-2 ortho-nitrofluorobenzene 

Downstream Products

• 1379604-79-1 4-(4-chlorophenyl)-1-((S)-3,4-dihydroxybutyl)-3-(3-((4-(4-(((R)-4-(dimethylamino)-1-(phenylthio)butan-2-yl)amino)-3-nitrophenylsulfonamido)phenyl)ethynyl)phenyl)-N-(3-(4-methylpiperazin-1-yl)propyl)-1H-pyrrole-2-carboxamide 
• 1379604-77-9 4-(4-chlorophenyl)-1-[(S)-3,4-dihydroxybutyl]-3-(3-{4-[4-(4-{[(R)-4-(dimethylamino)-1-(phenylthio)but-2-yl]amino}-3-nitrophenylsulfonamido)phenyl]-1H-1,2,3-triazol-1-yl}phenyl)-N-[3-(4-methylpiperazin-1-yl)propyl]-1H-pyrrole-2-carboxamide 

Relevant academic research and scientific papers

BCL-2/BCL-XL INHIBITORS FOR USE IN THE TREATMENT OF CANCER

Inhibitors of Bcl-2/Bcl-xL and compositions containing the same are disclosed. Methods of using the Bcl-2/Bcl-xL inhibitors in the treatment of diseases and conditions wherein inhibition of Bcl-2/Bcl-xL provides a benefit, like cancers, also are disclosed

Design of Bcl-2 and Bcl-xL inhibitors with subnanomolar binding affinities based upon a new scaffold

Employing a structure-based strategy, we have designed a new class of potent small-molecule inhibitors of the anti-apoptotic proteins Bcl-2 and Bcl-xL. An initial lead compound with a new scaffold was designed based upon the crystal structure of Bcl-xL an